Exhibit 99.2

2 This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding Edgewise’s cash runway, Edgewise’s expectations relating to its clinical trials and clinical development of sevasemten (EDG-5506) and EDG-7500, including statements regarding the number of individuals to be recruited, timing of completion of recruitment and over-enrollment of the GRAND CANYON trial; statements regarding the potential of, and expectations regarding, Edgewise’s product candidates and programs, including sevasemten and EDG-7500; statements regarding Edgewise’s milestones; statements regarding whether data from the GRAND CANYON trial could support a marketing application; statements regarding the Company’s plans to engage the FDA and European Medicines Agency; statements about sevasemten being the potential first treatment for Becker; and statements by Edgewise’s chief executive officer and chief medical officer and Craig M. McDonald, M.D. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Edgewise’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company, including the potential for Edgewise’s product candidates to cause serious adverse events; Edgewise’s ability to develop, initiate or complete clinical trials for, obtain approvals for and commercialize any of its product candidates; Edgewise’s ability to take advantage of potential benefits associated with designations granted by FDA and/or to maintain qualifications for applicable designations over time; the timing, progress and results of clinical trials for sevasemten and EDG-7500; Edgewise’s ability to enroll and maintain patients in clinical trials; Edgewise’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; the timing, scope and likelihood of regulatory filings and approvals; the potential for any clinical trial results to differ from preclinical, interim, preliminary, topline or expected results, including that the primary endpoint of the GRAND CANYON trial (change from baseline in NSAA) will be met even though it was not met as a secondary endpoint in the CANYON trial; the potential that the outcome of preclinical testing and early clinical trials, including the results from the CANYON trial, may not be predictive of the success of later clinical trials, including that the trends from the CANYON trial will also be seen, and will be statistically significant, in the GRAND CANYON trial; Edgewise may gain further insights from its analysis of the CANYON trial results over time, including Edgewise’s ongoing evaluation of additional secondary and exploratory endpoints; Edgewise’s ability to develop a proprietary drug discovery platform to build a pipeline of product candidates; Edgewise’s manufacturing, commercialization and marketing capabilities and strategy; the size of the market opportunity for Edgewise’s product candidates; the loss of key scientific or management personnel; competition in the industry in which Edgewise operates; Edgewise’s reliance on third parties; Edgewise’s ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that Edgewise files from time to time with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date of this presentation, and Edgewise assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. Forward Looking Statement

Agenda 1. Introduction 2. Becker muscular dystrophy and sevasemten 3. Topline results: Phase 2 CANYON trial in Becker 4. Sevasemten future development plans 5. Clinical perspectives on the results 6. Closing remarks 7. Q & A Distinguished Professor and Chair at the UC Davis Health Department of Physical Medicine and Rehabilitation Dr. Kevin Koch Dr. Craig M. McDonald Chief Executive Officer Dr. Joanne Donovan Chief Medical Officer

Focused on muscle science ● Global leader in muscle disease therapeutic development ● Deep knowledge of integrated muscle physiology ● Novel & holistic therapeutic approach to protect muscle Rapidly advancing portfolio ● Sevasemten pivotal program in muscular dystrophies including potential first treatment for Becker ● Advancing EDG-7500 in oHCM, nHCM, and other potential indications ● Novel cardiometabolic targets in discovery Unwavering patient commitment ● Mission-driven focus on unmet needs in severe muscle conditions ● Patients & families are critical voices in all development programs Abbreviations: oHCM, obstructive hypertrophic cardiomyopathy, nHCM, non-obstructive hypertrophic cardiomyopathy

5 The Evolution of Edgewise 2017 2020 2022 2023 2025 Founded as a muscle platform company targeting genetically driven muscle diseases EWTX completes IPO, expands development programs First program targeting muscular dystrophies Sevasemten, a fast skeletal myosin inhibitor, enters P1 in HVs and Becker MUSCULAR DYSTROPHY PROGRAM MILESTONES Sevasemten enters P2 in Duchenne Initiated GRAND CANYON pivotal cohort sevasemten in Becker 2021 2024 EDG-7500 identified as lead molecule with unique characteristics EDG-7500 characterized as a selective cardiac sarcomere modulator EDG-7500 enters the clinic; continued research on novel cardiometabolic targets Initiated CIRRUS-HCM, EDG-7500 P2 program in oHCM and nHCM CARDIOVASCULAR PROGRAM MILESTONES Identified a differentiated set of CV molecules as part of skeletal muscle counter-screen CV program initiated Sevasemten ARCH open label 24-month results in Becker Sevasemten, P2 CANYON 12-month results in Becker 2019 Initiated Becker ARCH open label study with sevasemten Abbreviations: HVs, healthy volunteers, CV, cardiovascular, oHCM, obstructive hypertrophic cardiomyopathy, nHCM, non-obstructive hypertrophic cardiomyopathy

6 ARCH, CANYON and the Evolution to GRAND CANYON Expedited the Development Timeline for Sevasemten in Becker • The Phase 2 CANYON study was originally designed as a dose-finding study to evaluate the effect of sevasemten on safety, pharmacokinetics, biomarkers, and function in individuals with Becker • 12-month data from the ARCH study supported the hypothesis that a reduction in contraction-induced muscle damage has the potential to preserve and improve muscle function while preventing disease progression • ARCH identified key factors, including the dose of sevasemten, to allow expansion of CANYON to include the GRAND CANYON cohort as a potentially registrational cohort with NSAA as the primary endpoint • GRAND CANYON is the first pivotal cohort of an investigational therapy for Becker. Data from GRAND CANYON, if positive, could support a marketing application 10 mg PO daily 15 mg PO daily Placebo 20 mg PO daily PIVOTAL Cohort 10 mg PO daily (18 mos.) Placebo 10 mg PO daily (12 mos.) Placebo N=40 Original CANYON Design Expanded CANYON/GRAND CANYON Design N=120 This strategic pivot significantly reduced development timelines to support a potential approval of sevasemten for individuals living with Becker

Becker Muscular Dystrophy and Sevasemten Dr. Joanne Donovan

8 I was told, ‘You’re lucky you don’t have Duchenne.’ It’s frustrating that you live longer, but you are constantly going downhill” – Individual living with Becker Our goal is to positively impact the course of Becker muscular dystrophy ● Becker is a rare, genetic, life-shortening, debilitating and degenerative neuromuscular disorder ● The disease predominately affects males and imposes significant physical, emotional, financial and social impacts on the individuals and their caregivers ● Individuals with Becker lose mobility, function and independence in the prime of their lives ● There is currently no treatment for Becker

9 Sevasemten is an investigational therapy that has not been approved for use in muscular dystrophies by any regulatory agency, as its safety and effectiveness have not been established for the treatment of these diseases. Abbreviations: CK, creatine kinase Sevasemten: A First-in-Class Fast Myofiber (Type II) Myosin Inhibitor Designed to Protect Against Contraction-Induced Muscle Injury Collapsed sarcomere Protected sarcomere Progressive disease pathology Contraction-induced muscle injury Sevasemten Prevention of contraction-induced muscle injury Excessive contraction induced muscle damage Duchenne Becker Sevasemten Therapeutic Hypothesis

Abbreviations: CK, Creatine Kinase; TNNI2, Fast Skeletal Muscle Troponin I 10 Elevated Circulating Levels of Muscle Injury Biomarkers, including CK and TNNI2, Indicate Ongoing Muscle Damage in Muscular Dystrophies Contraction-Induced Muscle Injury in Muscular Dystrophies Contraction induced muscle damage causes excessive degeneration Fast fibers are subsequently injured leading to release of muscle injury biomarkers into the circulation CK CK CK TNNI2 TNNI2 TNNI2 Circulating Levels of Muscle Injury Biomarkers Can be Measured to Determine Ongoing Muscle Damage in Muscular Dystrophies

11 PK, biomarkers and longer-term safety OLE Complete Function (NSAA), PK, biomarkers and longer-term safety OLE Recruiting GRASP Recruiting -01-002 24-Month, observational study Abbreviations: LGMD, limb-girdle muscular dystrophy; NSAA, North Star ambulatory assessment; PK, pharmacokinetics Our Commitment to Becker: Completed and Ongoing Clinical Trials Phase 2 Becker Pivotal Cohort Becker (NCT05291091) Becker Natural History Study (NCT05257473) Exercise challenge study OLE Complete Phase 2 Becker, LGMD2i, & McArdle Phase 1 Becker Open-label, safety, PK, function OLE Complete Open-label long-term safety, biomarkers and functional measures Enrolling by invitation Becker Open Label Extension Study (NCT06066580)

Topline Results

13 A Phase 2 Multi-Center Study to Assess Sevasemten Safety and Effect on Biomarkers in Adults with Becker * Adolescents were not selected based on NSAA Reference: NCT05160415 Abbreviations: CK, creatine kinase 5 mg or 12.5 mg PO daily Study design - 12 months Key Secondary: North Star Ambulatory Assessment (NSAA); change from baseline at month 12 Additional Endpoints: Safety, PK, biomarkers, timed function tests, MRI Month Placebo 10 mg PO daily Placebo 0 1 3 6 9 12 ADULTS ADOLESCENTS (ages 12-17) ADULT PRIMARY EFFICACY ENDPOINT Change from baseline in CK averaged across Months 6, 9 and 12 KEY INCLUSION CRITERIA Ambulatory males aged 12 to 50 years with a dystrophin mutation and a Becker phenotype, not on corticosteroids, with a NSAA between 5-32* PATIENTS ENROLLED Adults: 40 Adolescents: 29

14 Summary of Key Study Metrics * Trial sites in the US, UK and the Netherlands 16 sites 3 countries Enrollment: Largest Becker study to date Total of 80 patients screened and 69 patients enrolled: • Adults: 40 • Adolescents: 29 Low discontinuation rate • 4% overall • 2.5% in adult cohort (1 out of 40 enrolled) 99% of eligible participants enrolled in MESA open-label extension • Approximately, 85 Becker patients currently enrolled in MESA *

15 Becker Mutation Overview: Slow Progressor Genotypes were Largely Excluded with Functional Cut-Off Criteria Mutation type Adults (N=40) Adolescents (N=29) Becker mutations associated with progression 39 26 45-x 20 11 Other 19 15 None/very slow progression Becker mutations 1 3 X-51 1 (sevasemten) 2 (sevasemten) Del 48 0 0 45-55 (associates with late myopathy) 0 1 (sevasemten) Reference: Bello L., et. al., Sci Rep., 2016

16 Overview of Baseline Function in Safety Population *At baseline, 1 placebo and 9 sevasemten treated participants were unable to rise from floor Functional test Adults Sevasemten (n=28) Adults Placebo (n=12) ARCH (N=12) Mean total NSAA score, points (SD) 18.4 (7.66) 24.2 (8.19) 15.1 (8.4) Mean 4SC velocity, 1/seconds (SD) 0.22 (0.128) 0.34 (0.173) 0.19 (0.164) Mean RFF velocity, 1/seconds (SD)* 0.14 (0.114) 0.21 (0.128) 0.16 (0.196) Mean 10MWR velocity, meters/second (SD) 1.52 (0.731) 2.00 (0.884) 1.15 (0.521) Mean 100MTT velocity, meters/second (SD) 1.50 (0.856) 1.78 (0.782) 1.08 (0.496) Abbreviations: NSAA, North Star Ambulatory Assessment

17 Functional Measures Not Well Matched at Baseline; Patients in Sevasemten Group had Lower Baseline NSAA *At baseline, 1 placebo and 9 sevasemten treated participants were unable to rise from floor Functional test Adults Sevasemten (n=28) Adults Placebo (n=12) Difference (from placebo) P-value vs. Placebo Mean total NSAA score, points (SD) 18.4 (7.66) 24.2 (8.19) -5.8 0.04 Mean 4SC velocity, 1/seconds (SD) 0.22 (0.128) 0.34 (0.173) -0.12 0.02 Mean RFF velocity, 1/seconds (SD)* 0.14 (0.114) 0.21 (0.128) -0.07 0.09 Mean 10MWR velocity, meters/second (SD) 1.52 (0.731) 2.00 (0.884) -0.48 0.08 Mean 100MTT velocity, meters/second (SD) 1.50 (0.856) 1.78 (0.782) -0.28 0.32 The baseline imbalance observed is a direct consequence of a small study and should resolve in the larger GRAND CANYON cohort (n=120) Abbreviations: NSAA, North Star Ambulatory Assessment

18 Sevasemten was Well Tolerated: Overview of Treatment Emergent Adverse Events (TEAE) * A treatment emergent adverse event (TEAE) is any adverse event (AE) that starts during or after the first dose of investigational product through the end of the safety follow-up period Functional test Sevasemten (n=28) n (%) Placebo (n=12) n (%) Total (N=40) n (%) Any TEAE* 26 (92.9) 10 (83.3) 36 (90) Severe TEAE 0 (0) 0 (0) 0 (0) Serious Adverse Events 1 (3.6) 0 (0) 1 (2.5) Any drug related TEAE 16 (57.1) 5 (41.7) 21 (52.5) Discontinuation due to TEAE 1 (3.6) 0 (0) 1 (2.5) Deaths 0 (0) 0 (0) 0 (0)

19 Sevasemten was Well Tolerated: TEAEs Occurring in ≥5% of Total System Organ Class/Preferred Term Sevasemten (n=28) n (%) Placebo (n=12) n (%) Total (N=40) n (%) Any TEAE 26 (92.9%) 10 (83.3%) 36 (90%) Eye disorders Vision blurred 1 (3.6%) 2 (17%) 3 (8%) Gastrointestinal disorders Abdominal pain 1 (4%) 1 (8%) 2 (5.%) Vomiting 2 (7%) 0 (0%) 2 (5.%) General disorders and administration site conditions Fatigue 5 (18%) 3 (25%) 8 (20%) Chest discomfort 2 (7%) 0 (0%) 2 (5%) Influenza like illness 2 (7%) 0 (0%) 2 (5%) Infections and infestations COVID-19 6 (21%) 2 (17%) 8 (20%) Nasopharyngitis 6 (21%) 2 (17%) 8 (20.%) Upper respiratory tract infection 5 (18%) 2 (17%) 7 (18%) Influenza 4 (14%) 1 (8%) 5 (13%) Injury, poisoning and procedural complications Fall 8 (29%) 2 (17%) 10 (25%) Back injury 1 (4%) 1 (8%) 2 (5%) Investigations Ejection fraction decreased 0 (0%) 2 (17%) 2 (5%) Musculoskeletal and connective tissue disorders Arthralgia 2 (7%) 1 (8%) 3 (8%) Back pain 3 (11%) 0 (0%) 3 (8%) Osteopenia 2 (7%) 0 (0%) 2 (5%) Tendonitis 2 (7%) 0 (0%) 2 (5%) Nervous system disorders Headache 9 (32%) 2 (17%) 11 (28%) Dizziness 9 (32%) 0 (0%) 9 (23%) Somnolence 5 (18%) 1 (8%) 6 (15%) Migraine 3 (11%) 1 (8%) 4 (10%) Dizziness postural 2 (7%) 1 (8%) 3 (8%) Respiratory, thoracic and mediastinal disorders Oropharyngeal pain 4 (14%) 0 (0%) 4 (10%) Cough 3 (11%) 0 (0%) 3 (8%) Nasal congestion 2 (7%) 0 (0%) 2 (5%)

20 Statistically Significant Decrease in the Primary Endpoint of CK: 28% Reduction vs Placebo Note: CK values are log-transformed. LS (least squares) means, LS mean differences and CIs were back-transformed to percent scale Abbreviations: CFB, change from baseline, CI, confidence interval, CK, creatine kinase CK between-group difference LSMean: -28% (95% CI -44% to -6%); p-value = 0.02 Placebo Sevasemten -40 -20 0 20 40 % CFB CK (Avg 6-12 mo) 0 3 6 9 12 -50 0 50 100 Time (months) % CFB in CK Average 6 -12 months Sevasemten Placebo CK showed rapid and sustained decreases with sevasemten treatment

21 TNNI2 Decreased 77% from Baseline in the Sevasemten Treatment Group vs Placebo TNNI2 between-group difference LSMean: -77% (95% CI -89% to 51%); p-value < 0.001 Average 6 -12 months Sevasemten Placebo 0 3 6 9 12 -100 0 100 200 Time (months) % CFB in TNNI2 Placebo Sevasemten -100 -50 0 50 100 150 % CFB TNNI2 (Avg 6-12 mo) Note: TNNI2 values are log-transformed. LS means, LS mean differences and CIs were back-transformed to percent scale Abbreviations: CFB, change from baseline, CI, confidence interval, TNNI2, troponin I2 TNNI2, an on-target biomarker of fast muscle fiber damage, also demonstrated rapid and sustained decreases with sevasemten treatment

22 Key Secondary Endpoint: NSAA Remained Stable Over Time in Sevasemten Group 0 3 6 9 12 -3 -2 -1 0 1 2 Time (months) CFB Total NSAA Score NSAA between-group difference LSMean: 1.12 (95% CI -0.4 to 2.7); p-value = 0.16 Sevasemten Placebo Positive trends in NSAA favoring sevasemten with placebo declining in line with natural history Abbreviations: NSAA, North Star Ambulatory Assessment

23 63% of Patients Treated with Sevasemten Showed Stable or Improved Function After 12 Months Sevasemten NSAA Responder Analysis -6 -4 -2 2 4 6 -6 -4 -2 2 4 6 Placebo (n=12) Sevasemten (n=27) 63% 33% 67% 37% Stability or Improvement Odds Ratio: 3.4 (p=0.16) Abbreviations: NSAA, North Star Ambulatory Assessment

24 Trends in Other Functional Measures Favor Sevasemten Treatment Arm -4 -2 0 2 4 RFF Velocity 4SC Velocity 100MTT Velocity 10MWR Velocity NSAA Standardized Statistics (95% CI) 1.12 0.075 0.055 0.024 -0.005 LSMean Difference * At baseline, 9 sevasemten and 1 placebo treated participants were unable to rise from floor. At Month 12, 9 sevasemten and 2 placebo treated participants were unable to rise from floor Note: For the figures, LSM differences and CIs were standardized by dividing by the SE. LSM differences presented on the right of the figure are on original scale (without SE adjustment) * Favors Placebo Favors Sevasemten Abbreviations: NSAA, North Star Ambulatory Assessment, CI, confidence interval

25 Summary of Trial Results • Sevasemten treated patients showed stabilization of NSAA with trends toward improvement • Placebo group (n=12) declined in line with natural history • Primary endpoint achieved: 28% average decrease in CK versus placebo (p=0.02) • Plasma TNNI2 decreased 77% from baseline versus placebo (p<0.001) • Well-tolerated, at all doses, in adults and adolescents • No safety concerns identified • The imbalance between groups confounded interpretation of a few endpoints (e.g., MRI); evaluation of the full data set ongoing Safety Biomarkers Function Secondary & Exploratory Abbreviations: CK, creatine kinase, NSAA, North Star Ambulatory Assessment

Sevasemten Future Development Plans

27 9 15 Global, Multi-Center, Placebo-Controlled Pivotal Cohort Assessing Efficacy & Safety of Sevasemten in Becker Abbreviations: PO, by mouth; NSAA, North Star Ambulatory Assessment PRIMARY ENDPOINT NSAA at 18 months KEY INCLUSION CRITERIA Adult individuals with Becker with NSAA 5-32, not taking corticosteroids ENROLLMENT >120 Study design - 18 months 10mg PO daily Screening 0 1 3 6 Additional Endpoints Timed function tests (TFTs), biomarkers of muscle damage, MRI, patient reported outcomes (PROs), safety Month POTENTIAL REGISTRATIONAL COHORT 12 POWERED AT >90% for observing a difference corresponding to the natural history NSAA decline of 1.2 points/year Placebo R 2:1 18

28 GRAND CANYON Powered at 96% to Show a 1.68 Point NSAA Difference at 18 Months p<0.05 Treatment Difference Power Calculation Assumptions: • N=120 patients with 2:1 randomization • Month 12 CANYON treatment difference = 1.12 • Assumed 50% increase in NSAA treatment effect at month 18 vs month 12 ( = 1.68) • 10% drop-out rate • Standard deviation () = 2.16 • Tipping point = 0.87 (represents point where the p-value is ~0.05 given the study size and assumed standard deviation based on t-test) Power: 96% -2 -1 0 1 2 3 4 Abbreviations: NSAA, North Star Ambulatory Assessment

29 Sevasemten for Becker Next Steps *European sites include the UK, Netherlands, Belgium, Denmark, Spain, France, Germany and Italy Increased confidence in GRAND CANYON future success based on sevasemten clinical experience to date, Becker natural history data, and internal modeling CANYON results support engagement with FDA & EMA about marketing authorization filing strategies for sevasemten in Becker GRAND CANYON is near full enrollment in 51 sites across the United States, Europe*, New Zealand, Australia and Israel; on track to over-enroll by Q1 2025 1 2 To date, 99% of eligible Becker participants who have completed ARCH, CANYON, GRAND CANYON and DUNE have enrolled in MESA 3 4

CANYON Clinical Implications and Sevasemten’s Potential Role in Becker Dr. Craig M. McDonald

31 Reference: 1. Bello L, et al. 2016. 2. De Wel B, et al. Eur J Neurol. 2024. 3. Van de Velde NM, et al. Neurology. 2021.;4. Bello L et al 2024 WMS; 95% CI shown Natural History Data in Becker Support that Functional Decline, Measured by NSAA, is Consistent and Predictable 0 1 2 3 4 5 -10 -8 -6 -4 -2 0 Years of Observation Change in NSAA Natural history of Becker muscular dystrophy • NSAA is utilized in muscular dystrophy natural history studies to longitudinally assess function • Multiple natural history studies in individuals with Becker demonstrate a NSAA average score decline of 1.0 to 1.8 points annually . 1,2,3 • Becker Natural history studies support that NSAA decline is consistent in Becker patients who are already progressing

32 A Clinician’s Perspective on How to Interpret a 1-point NSAA Change in Becker From using the toilet independently… …to asking for help to get up from the toilet. …to requiring assistance from another person or mobility device. …to requiring someone else’s help to get back up. From using stairs or steps… From being able to get up from a fall… For individuals living with Becker, this decline could look like: Abbreviations: NSAA, North Star Ambulatory Assessment

Closing Remarks Kevin Koch, CEO

We Aim to Change the Lives of Individuals with Becker ~12,000 PEOPLE WITH BECKER IN US, EU-5 & JAPAN ~16 AGE PEOPLE WITH BECKER CAN BECOME MOBILITY DEVICE DEPENDENT • Source: Parent Project Muscular Dystrophy: Fifteen Year Registry Report; Edgewise Therapeutics independent quantitative and qualitative market research (Bluestar BioAdvisors); Edgewise research; Emery AE, Neuromuscul. Disord., 1991; MD STARnet Data and Statistics; Duchenne muscular dystrophy. National Center for Advancing Translational Sciences; Duan D et al., Nat. Rev. Dis. Primers, 2021 0 APPROVED THERAPIES

35 Abbreviations: HV, healthy volunteers; oHCM, obstructive hypertrophic cardiomyopathy; nHCM, non-obstructive hypertrophic cardiomyopathy; CV, cardiovascular; IND, Investigational New Drug application; POC, proof of concept Edgewise Upcoming Value-Generating Milestones H2 2024 H1 2025 H2 2025 Becker Duchenne Skeletal Sevasemten Hypertrophic Cardiomyopathy Cardiac EDG-7500 Phase 2 LYNX & FOX Controlled dose-ranging data Phase 3 trial Initiation Phase 2 CANYON 1-year placebo-controlled data Phase 1/Phase 2 EDG-7500 data in HVs & oHCM Phase 2 28-day study Initiate in oHCM & nHCM Phase 2 28-day study Initial Data readout ✓ ✓ GRAND CANYON Recruitment complete (Q1) Cardiometabolic Drug In vivo POC Phase 2 12-week oHCM & nHCM ✓ EDG-CV candidate IND in HF

36 As of September 30, 2024 Well-Capitalized to Execute Important Milestones Across Both EDG-7500 & Sevasemten (1) DEBT (1) $0 CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES ~$493M COMMON SHARES OUTSTANDING (NASDAQ: EWTX) ~94M CASH RUNWAY THROUGH 2027

37 Q & A